Trends in Disease Burden of Chronic Lymphocytic Leukemia at the Global, Regional, and National Levels From 1990 to 2019, and Projections Until 2030: A Population-Based Epidemiologic Study

Ou, Yvonne; Long, Yichen; Ji, Lili; Zhan, Yanxia; Qiao, Tiankui; Wang, Xiangdong; Chen, Hao; Cheng, Yunfeng

doi:10.3389/fonc.2022.840616

Cited by 33 publications

(18 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic Lymphoid Leukemia (CLL): It is considered as a disease of older adults with a median age of 70 at diagnosis. Molecular characterization of the pathology has rendered the opportunity of developing new drugs against key targets such as BTK, BCL-2 and PI3K which application has increased the 5-year overall survival up to 86% ( 3 ).…”

Section: Introductionmentioning

confidence: 99%

Reactive Oxygen Species and Metabolism in Leukemia: A Dangerous Liaison

Romo-González

Ijurko²,

Hernández‐Hernández³

2022

Front. Immunol.

View full text Add to dashboard Cite

Reactive oxygen species (ROS), previously considered toxic by-products of aerobic metabolism, are increasingly recognized as regulators of cellular signaling. Keeping ROS levels low is essential to safeguard the self-renewal capacity of hematopoietic stem cells (HSC). HSC reside in a hypoxic environment and have been shown to be highly dependent on the glycolytic pathway to meet their energy requirements. However, when the differentiation machinery is activated, there is an essential enhancement of ROS together with a metabolic shift toward oxidative metabolism. Initiating and sustaining leukemia depend on the activity of leukemic stem cells (LSC). LSC also show low ROS levels, but unlike HSC, LSC rely on oxygen to meet their metabolic energetic requirements through mitochondrial respiration. In contrast, leukemic blasts show high ROS levels and great metabolic plasticity, both of which seem to sustain their invasiveness. Oxidative stress and metabolism rewiring are recognized as hallmarks of cancer that are intimately intermingled. Here we present a detailed overview of these two features, sustained at different levels, that support a two-way relationship in leukemia. Modifying ROS levels and targeting metabolism are interesting therapeutic approaches. Therefore, we provide the most recent evidence on the modulation of oxidative stress and metabolism as a suitable anti-leukemic approach.

show abstract

Section: Introductionmentioning

confidence: 99%

Reactive Oxygen Species and Metabolism in Leukemia: A Dangerous Liaison

Romo-González

Ijurko²,

Hernández‐Hernández³

2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…This finding was consistent with a previous study by Ou and his colleague. 7 are multiple for this. First, treatment response rates were higher in females than males, independent of the stage of CLL and age.…”

Section: N (%)mentioning

confidence: 99%

Mortality trends of chronic lymphocytic leukaemia in the United States with the emergence of targeted therapy

Tan,

Yeo,

Tan

et al. 2023

Br J Haematol

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) accounts for more than one-third of the new cases of leukaemias in the United States. 1 Over the past decades, the treatment landscape for CLL has witnessed significant changes. In the light of the revolutionary progress made in treatment modalities for CLL, we aimed to analyse CLL mortality trends in the past two decades to provide a population-based perspective on the impact of these advancements on patient outcomes and also to identify potential demographic disparities.Death certificate data from the US Centers for Disease Control and Prevention's Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) was analysed from 1999 to 2020 to determine the longitudinal trends of CLL among the US population aged ≥35 years. Those aged below 35 years were excluded due to low case counts. We selected CLL (ICD-10 C91.1) as the underlying cause of death. We measured age-adjusted mortality rates (AAMRs) of CLL per 100 000 individuals by standardizing to the year 2000 US census population. We plotted the AAMRs per 100 000 individuals to determine the trends from 1999 to 2020.There were 97 186 deaths attributed to CLL from 1999 to 2020. Table 1 shows the baseline demographics of patients who met the inclusion criteria. Overall, there was a decrease in the AAMR of CLL from 3.23 (95% CI, 3.13-3.32) per 100 000 individuals in 1999 to 2.05 (95% CI, 1.99-2.11) per 100 000 individuals in 2020, with the average annual percent change (AAPC) at −2.09 (95% CI, −2.69, −1.49). The annual percent change (APC) was greater in the recent decade from 2011 to 2020 than the previous decade from 1999 to 2011 (−3.16 [95% CI, −3.83, −2.84] vs. −1.56 [95% CI, −2.01, −1.11]) (Table 2). Males had a higher AAMR of CLL than females (3.78 [95% CI, 3.75-3.81] vs. 1.72 [95% CI, 1.71-1.74] per 100 000 individuals). The highest AAMR was observed among non-Hispanic White males (4.14 [95% CI, 4.10-4.17] per 100 000 individuals), followed by non-Hispanic Black males (3.48 [95% CI,] per 100 000 individuals), non-Hispanic White females (1.88 [95% CI,] per 100 000 individuals) and non-Hispanic Black females (1.61 [95% CI, 1.55-1.67] per 100 000 individuals) (Figure S1a). Those who lived in the Midwest region and the rural region had the highest AAMR respectively (2.93 [95% CI, 2.89-2.97] per 100 000 individuals vs. 2.87 [95% CI, 2.83-2.91] per 100 000 individuals) (Figure S1b).Our study demonstrates that the AAMR of CLL decreased by 2% annually from 1999 to 2020. This aligns with

show abstract

“…Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in Western countries [1]. In 2019, the global age-standardized incidence rate was 1.28 cases per 100,000 persons [2]. The median age at diagnosis is 70 years old [3] and the disease is more common in male patients (global sex ratio: 1.4 men/women) [2].…”

Section: Introductionmentioning

confidence: 99%

Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study

DARTIGEAS,

QUINQUENEL,

YSEBAERT

et al. 2024

Preprint

View full text Add to dashboard Cite

We conducted an observational study (FIRE) to understand the effectiveness and safety outcomes of ibrutinib in patients with chronic lymphocytic leukemia (CLL) in France, after a maximum follow-up of five years. Patients were included according to the French marketing authorization in 2016 (i.e. patients with relapsed or refractoryCLL or to previously untreated CLL patients with deletion 17p and/or TP53 mutations unsuitable for chemoimmunotherapy) and could have initiated ibrutinib more than 30 days prior their enrolment in the study (i.e. retrospective patients) or between 30 days before and 14 days after their enrolment (i.e. prospective patients). The results showed that in the effectiveness population (N=388), the median progression-free survival (PFS) was 53.1 (95% CI: 44.5-60.5) months for retrospective patients and 52.9 (95% CI: 40.3-60.6) months for prospective patients and no difference was shown between the PFS of patients who had at least one dose reduction versus the PFS of patients without dose reduction (p=0.7971 for retrospective and p=0.3163 for prospective patients). For both retrospective and prospective patients, the median overall survival was not reached. The most frequent treatment-emergent adverse event of interest was infections (57.6% retrospective; 71.4% prospective). A total of 14.6% of the retrospective patients and 22.4% of the prospective patients had an adverse event leading to death. Our findings on effectiveness were consistent with other studies and the fact that patients with dose reductions had similar PFS than patients without dose reduction is reassuring. No additional safety concerns than those already mentioned in previous studies could be noticed. Trial registration ClinicalTrials.gov, NCT03425591. Registered 1 February 2018 – Retrospectively registered.

show abstract

Trends in Disease Burden of Chronic Lymphocytic Leukemia at the Global, Regional, and National Levels From 1990 to 2019, and Projections Until 2030: A Population-Based Epidemiologic Study

Cited by 33 publications

References 56 publications

Reactive Oxygen Species and Metabolism in Leukemia: A Dangerous Liaison

Reactive Oxygen Species and Metabolism in Leukemia: A Dangerous Liaison

Mortality trends of chronic lymphocytic leukaemia in the United States with the emergence of targeted therapy

Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study

Contact Info

Product

Resources

About